An affordable colorectal cancer diagnostic test with exceptional accuracy
The Oricol™ CRC PreView test – currently in development – analyses Oricol™ samples to determine far more accurately whether a patient has colorectal cancer.
Oricol™ CRC PreView will be the most accurate way of detecting colorectal cancer, comparable to the gold standard of colonoscopy. Our extraordinary sensitivity and specificity means it almost never misses CRC if it is present, and almost never gives a false alarm.
Despite its exceptional accuracy, Oricol™ CRC PreView will be highly affordable, making it an excellent choice for health services looking to balance the health-economic equation, and for whom colonoscopies represent a huge cost burden.
Our test can potentially be used for all patients in all settings, with very few exceptions. Unlike invasive procedures, which can have complications, it poses no risk to the patient. It requires no preparation, and is easy to administer for any trained professional.
Many other diagnostic tests are unpleasant, as they require the patient to sample their own stool. This leads to high rates of non-compliance, with patients putting off the test or opting out. The Oricol™ collection procedure is quick and painless.
How does Oricol™ CRC PreView compare to the alternatives?
StoolFOBt and qFIT
The most common colorectal cancer tests are FOBt and qFIT, both of which require a stool sample. At best, these tests have a sensitivity of around 79% and specificity of 95%. The means that 21% of cancer cases are missed, and 5% of positive results are false alarms.
StoolDNA from Stool
More sophisticated tests on the market use gene sequencing techniques with stool samples. The market leading test has a sensitivity of 92% and a specificity of 92%. These tests come at significant expense.
Although blood tests are extremely effective in other areas of medicine, they do not perform well for the detection and diagnosis of GI disease. The best test currently on the mark has a sensitivity of 72%.
Mucosal DNAOricol CRC PreView
Oricol™ CRC PreView uses cutting edge gene sequencing techniques with a sample of the rectal mucosa taken using the Oricol™ device. It will have a sensitivity and specificity of 99%+, making it as accurate as a colonoscopy.
Oricol™ CRC PreView is currently in development
The test is not yet available, but we are progressing rapidly toward this point.